Automated screening of primary cell-based aptamers for targeting and therapy of pancreatic cancer

作     者：Zhukang Guo Baijiang Jin Yile Fang Lian Jin Song Li Yan Deng Zhu Chen Hui Chen Yuanying Zhang Rabia Usman Nongyue He Zhukang Guo;Baijiang Jin;Yile Fang;Lian Jin;Song Li;Yan Deng;Zhu Chen;Hui Chen;Yuanying Zhang;Rabia Usman;Nongyue He

作者机构：State Key Laboratory of Digital Medical EngineeringSchool of Biological Science and Medical EngineeringSoutheast UniversityNanjing 210096China Hunan Key Laboratory of Biomedical Nanomaterials and DevicesHunan University of TechnologyZhuzhou 412007China Department of Molecular BiologyJiangsu Cancer HospitalNanjing 210009China 

出 版 物：《Chinese Chemical Letters》 (中国化学快报（英文版）)

年 卷 期：2024年第35卷第2期

页      面：300-304页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Key Research and Development Program of China(Nos.2017YFA0205301 and 2018YFC1602905) National Natural Science Foundation of China(Nos.62071119,62075098,81902153,61527806) the Open Funding of State Key Laboratory of Oral Diseases(No.SKLOD2022OF05) 

主　　题：Aptamer Cell-SELEX Automatic instrument Combination therapy Pancreatic cancer 

摘      要：Although it has been developed for many years, nucleic acid aptamer screening technology still fails to be widely used, a considerable part of it is due to the variability of tumor cell morphology, which leads to the use of immortalized cell lines in the laboratory to screen nucleic acid aptamers for recognition ability of tumor cells in the diseased *** address this, primary cells that can be stably passaged were isolated and extracted from spontaneous tumors of genetically engineered pancreatic ductal adenocarcinoma model mice in this ***, an automated screening instrument for nucleic acid aptamers developed autonomously by our group was used to perform efficient aptamer screening using a limited number of cells, and the obtained nucleic acid aptamers were affinity verified at the cellular ***, to answer the question of the cell growth environment difference on the recognition ability of nucleic acid aptamers, we verified its targeting ability to tumors in vivo on a nude mice xenograft tumor model, and further used a common antitumor drug doxorubicin combined with nucleic acid aptamers to verify the drug loading ability of this aptamer combined with the targeting therapeutic ability.